JP2021512894A5 - - Google Patents

Info

Publication number
JP2021512894A5
JP2021512894A5 JP2020542552A JP2020542552A JP2021512894A5 JP 2021512894 A5 JP2021512894 A5 JP 2021512894A5 JP 2020542552 A JP2020542552 A JP 2020542552A JP 2020542552 A JP2020542552 A JP 2020542552A JP 2021512894 A5 JP2021512894 A5 JP 2021512894A5
Authority
JP
Japan
Prior art keywords
composition
subject
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512894A (ja
JP7397797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016503 external-priority patent/WO2019156929A1/en
Publication of JP2021512894A publication Critical patent/JP2021512894A/ja
Publication of JP2021512894A5 publication Critical patent/JP2021512894A5/ja
Priority to JP2023203652A priority Critical patent/JP2024023490A/ja
Application granted granted Critical
Publication of JP7397797B2 publication Critical patent/JP7397797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542552A 2018-02-07 2019-02-04 治療用化合物および組成物 Active JP7397797B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023203652A JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627435P 2018-02-07 2018-02-07
US62/627,435 2018-02-07
PCT/US2019/016503 WO2019156929A1 (en) 2018-02-07 2019-02-04 Therapeutic compounds and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203652A Division JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Publications (3)

Publication Number Publication Date
JP2021512894A JP2021512894A (ja) 2021-05-20
JP2021512894A5 true JP2021512894A5 (cg-RX-API-DMAC7.html) 2022-02-14
JP7397797B2 JP7397797B2 (ja) 2023-12-13

Family

ID=67548561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542552A Active JP7397797B2 (ja) 2018-02-07 2019-02-04 治療用化合物および組成物
JP2023203652A Pending JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023203652A Pending JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Country Status (10)

Country Link
US (2) US11691962B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749662A4 (cg-RX-API-DMAC7.html)
JP (2) JP7397797B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200118088A (cg-RX-API-DMAC7.html)
CN (1) CN111902404A (cg-RX-API-DMAC7.html)
AU (1) AU2019217366B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016123A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089970A1 (cg-RX-API-DMAC7.html)
IL (2) IL276563B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019156929A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
WO2019156929A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
WO1999037668A1 (de) 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombininhibitoren
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
CA2336003A1 (en) 1998-06-25 1999-12-29 Zhongmin Xu Amidino and guanidino azetidinone tryptase inhibitors
WO2000005204A1 (en) 1998-07-23 2000-02-03 Shionogi & Co., Ltd. MONOCYCLIC β-LACTAM COMPOUNDS AND CHYMASE INHIBITORS CONTAINING THE SAME
KR20060120601A (ko) 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
CA2648522A1 (en) 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
WO2010147791A1 (en) * 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
JP5844287B2 (ja) 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのマクロ環
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US9499532B2 (en) * 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
US20190315711A1 (en) 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2019156929A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
CA3117549A1 (en) 2018-10-30 2020-05-07 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
CA3117470A1 (en) 2018-10-30 2020-05-07 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
KR20210119432A (ko) 2019-01-29 2021-10-05 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물

Similar Documents

Publication Publication Date Title
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2004532250A (ja) 線維性疾患又は他の適応症の治療方法
US20210261524A1 (en) Therapeutic compounds and compositions
JP2015164972A5 (cg-RX-API-DMAC7.html)
RU2012144332A (ru) Циклоалкил-замещенное производное имидазола
ES2694375T3 (es) Composiciones para el tratamiento de la hipertensión y/o de la fibrosis
JP2024507414A5 (cg-RX-API-DMAC7.html)
JP2019529460A5 (cg-RX-API-DMAC7.html)
JP2022545158A5 (cg-RX-API-DMAC7.html)
JP2009521472A (ja) 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
JP2017535546A (ja) 新規な方法
JP2017535546A5 (cg-RX-API-DMAC7.html)
US20210253550A1 (en) Therapeutic compounds and compositions
US20070259913A1 (en) Prophylaxis of thromboembolic events in cancer patients
AU2019217366B2 (en) Therapeutic compounds and compositions
US20060241084A1 (en) Inhibition of vascular endothelial growth factor
CN101489549A (zh) 直接凝血酶抑制剂在心血管领域的新的适应症
CN108623591B (zh) 一种哌尼诺安化合物的用途
RU2813780C2 (ru) Терапевтические соединения и композиции
EP1551381A2 (en) Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor
JP2015526493A (ja) 冠動脈バイパス移植術を受けることが予定されている患者の非st上昇型急性冠症候群の治療において使用するためのオタミキサバン
CN116134025A (zh) 酰胺膦氧类衍生物及其制备方法和用途
JP2023541655A (ja) 治療用化合物、組成物およびその使用方法
RU2021115313A (ru) Терапевтические соединения и композиция
CA2500385A1 (en) Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor